178,203 research outputs found
Interview with Dr. Elizabeth R. Varon
No full textCENFAD community interview with Dr. Elizabeth R. Varon, Langbourne M. Williams Professor of American History at the University of Virginia, concerning her book Armies of Deliverance: A New History of the Civil War (Oxford University Press, 2019
Cwbr Author Interview: Appomattox: Victory, Defeat, And Freedom At The End Of The Civil War
No full textInterview with Elizabeth Varon, the Langbourne M. Williams Professor of American History at the University of Virginia Interviewed by Michael Frawley
Civil War Book Review (CWBR): Today the Civil War Book Review is proud to speak with Elizabeth Varon, the Langbourne M. Williams Professor of American History at the University of Virginia, and discuss her recent book Appomattox: Victory, Defeat, and Freedom at the End of the Civil War. Thank you for joining us today. Elizabeth Varon (EV): It is a delight to do so, thank you
Armies of Deliverance A New History of the Civil War
No full textIn Armies of Deliverance, Elizabeth Varon offers both a sweeping narrative of the Civil War and a bold new interpretation of Union and Confederate war aim
Further delineation of the Yunis-Varon syndrome
No full textA boy with intrauterine growth retardation, microcephaly, dysostosis of the skull, hypoplastic facial bones, labiogingival retraction, agenesis of the clavicles, distal aphalangia, and severely hypoplastic thumbs and halluces is described. The features are consistent with the Yunis-Varon syndrome. Review of published reports shows this to be a generalised disorder with variable manifestations in the skeletal, ectodermal, and cardiovascular systems. The consanguinity of the parents of the present case is in agreement with autosomal recessive inheritanc
Disunion! The Coming of the American Civil War, 1789-1859. By Elizabeth R. Varon. (Chapel Hill: University of North Carolina Press, 2008. xiv, 455 pp. $30.00, ISBN 978-0-8078-3232-5.)
No full textElizabeth R. Varon has written an ambitious book that seeks to reimagine the causes of the Civil War. She does this by focusing on one idea—that of disunion. Varon argues that the word disunion was a catalyst of sectionalism. In her words, “disunion rhetoric shaped and limited Americans\u27 political and moral imagination, ultimately discouraging a politics of compromise and lending an aura of inexorability to the cataclysmic confrontation of North and South” (p. 2). Varon is careful to limit her argument. Disunion talk did not cause the Civil War, she acknowledges—slavery did. But that word, and the multiple meanings and images that it assumed (Varon sets out the five categories of prophecy, threat, accusation, process, and program), did facilitate and characterize the political conflict over slavery
Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations
No full textBen Varon,1 Netanel A Horowitz,1,2 Hazim Khatib1 1Department of Hematology and Bone Marrow Transplantation, Rambam Healthcare Campus, Haifa 3109601, Israel; 2Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, IsraelCorrespondence: Ben Varon, Department of Hematology and Bone Marrow Transplantation, Rambam Healthcare Campus, Haifa, 3109601, Israel, Tel +972-4-7778026, Email [email protected]: This article provides an overview of the novel treatments focusing on the class of bispecific T cell engagers (BiTEs) for the treatment of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), the two most prevalent subtypes of B cell non-Hodgkin lymphomas (B-NHL). After a brief outline of these diseases, the difficulties in the management of relapsed or refractory (R/R) disease are highlighted. There are currently 4 main BiTEs showing promise in treating R/R B-NHL—glofitamab, epcoritamab, mosunetuzumab, and odronextamab. Although the rational of their mechanism of action is similar, there are significant differences in their respective clinical trial design, reported outcomes, and the final FDA approvals. Considerations for selecting a specific BiTE therapy, including treatment duration, cost, administration route, adverse effects, and impact on quality of life, are also discussed. Patient preferences and shared decision making should be acknowledged by healthcare providers. Finally, the importance of personalized treatment strategies and ongoing research to optimize outcomes in the evolving landscape of R/R B-NHL therapy cannot be overstated.Keywords: bispecific, BiTE, glofitamab, epcoritamab, mosunetuzumab, odronextama
Appropriate Similarity Measures for Author Cocitation Analysis
No full textWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Comment on: Corpus callosum hypoplasia and associated brain anomalies in Nijmegen breakage syndrome.
No full text"Closing the R&D Gap, Evaluating the Sources of R&D Spending"
No full textBoth spending and tax policies have been implemented in the United States with the goal of stimulating private sector research and development (R&D). Karier questions whether current R&D policy, especially the research and experimentation tax credit, can contribute to closing the gap between nondefense expenditures on R&D in the United States and such expenditures in other countries, such as Japan and Germany. He also explores possible changes to our current R&D policy to make it more effective.
- …
